End-of-day quote
Taipei Exchange
06:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
94.7
TWD
|
+2.82%
|
|
-3.76%
|
+11.28%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
3,270
|
2,461
|
3,734
|
7,445
|
9,137
|
Enterprise Value (EV)
1 |
3,270
|
2,461
|
3,734
|
7,445
|
9,137
|
P/E ratio
|
39.4
x
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
5.23%
|
4.7%
|
5.28%
|
Capitalization / Revenue
|
-
|
0.96
x
|
1.18
x
|
1.89
x
|
1.93
x
|
EV / Revenue
|
-
|
0.96
x
|
1.18
x
|
1.89
x
|
1.93
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
16.2
x
|
53.2
x
|
-102
x
|
17.2
x
|
FCF Yield
|
-
|
6.19%
|
1.88%
|
-0.98%
|
5.82%
|
Price to Book
|
-
|
-
|
1.25
x
|
2.13
x
|
2.31
x
|
Nbr of stocks (in thousands)
|
88,390
|
78,112
|
78,112
|
87,481
|
96,487
|
Reference price
2 |
37.00
|
31.50
|
47.80
|
85.10
|
94.70
|
Announcement Date
|
3/29/21
|
3/29/22
|
3/28/23
|
3/21/24
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
2,571
|
3,169
|
3,930
|
4,745
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
161.4
|
341.6
|
543.3
|
720
|
Operating Margin
|
-
|
6.28%
|
10.78%
|
13.82%
|
15.17%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
101.8
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
0.9400
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
152.3
|
70.16
|
-72.65
|
532
|
FCF margin
|
-
|
5.93%
|
2.21%
|
-1.85%
|
11.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
2.500
|
4.000
|
5.000
|
Announcement Date
|
3/29/21
|
3/29/22
|
3/28/23
|
3/21/24
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
739.8
|
744
|
928.1
|
933.3
|
934.4
|
1,134
|
1,066
|
1,180
|
1,130
|
1,368
|
EBITDA
|
-
|
-
|
-
|
211.4
|
273.5
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
60.92
|
71.54
|
101.8
|
114.6
|
171.2
|
155.8
|
124.9
|
182
|
188
|
226
|
Operating Margin
|
8.24%
|
9.62%
|
10.96%
|
12.28%
|
18.32%
|
13.73%
|
11.72%
|
15.42%
|
16.64%
|
16.52%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/16/22
|
8/15/22
|
5/15/23
|
8/14/23
|
11/14/23
|
3/21/24
|
5/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
152
|
70.2
|
-72.7
|
532
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
11.8%
|
13.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
6.39%
|
7.41%
|
Assets
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
38.30
|
39.90
|
41.10
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
190
|
287
|
506
|
400
|
Capex / Sales
|
-
|
7.38%
|
9.05%
|
12.89%
|
8.43%
|
Announcement Date
|
3/29/21
|
3/29/22
|
3/28/23
|
3/21/24
|
-
|
Last Close Price
94.7
TWD Average target price
124
TWD Spread / Average Target +30.94% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.28% | 275M | | +12.05% | 126B | | -9.24% | 10.89B | | +0.29% | 9.02B | | +36.99% | 5.41B | | -21.98% | 4.6B | | +8.02% | 3.44B | | -10.32% | 2.74B | | -12.33% | 2.06B | | -13.53% | 1.96B |
Medical Devices & Implants
|